Background: Paclitaxel-coated balloons (PCBs) are widely used for femoropopliteal artery (FPA) diseases. However, data on recurrence and recurrence patterns after PCB angioplasty are limited. This study investigated the association between recurrence patterns, baseline characteristics, and clinical outcomes in the cases following PCB angioplasty.
Methods: This multicenter, retrospective study included 1159 limbs in 1031 patients treated for de novo FPA lesions using PCBs. Patients were classified into three groups (patency, restenosis, and reocclusion) according to patency or recurrence patterns within 2 years after the index PCB angioplasty. The primary outcome was the incidence of target lesion revascularization (TLR), and the secondary outcome was the pattern of re-recurrence within 2 years following TLR using PCBs.
Results: When comparing the three groups, reocclusive cases were characterized by more complex lesions, including chronic total occlusion, at baseline. Following the index PCB angioplasty, approximately 70% of recurrent cases underwent TLR, which was performed more frequently in reocclusive than in restenotic cases (82.1% vs 63.7%). Conversely, a higher percentage of restenotic cases did not require TLR compared to reocclusive cases (10.3% vs 27.8%). In cases where TLR was performed using PCBs, the rate of re-recurrence with occlusive morphology was significantly higher in reocclusive than in restenotic cases (52.3% vs 24.3%).
Conclusions: After PCB angioplasty for FPA lesions, symptomatic recurrence and requirement for TLR were more frequent in reocclusive cases. Even after TLR using PCBs, reocclusive cases tend to recur with occlusion.
{"title":"Recurrence patterns and clinical outcomes following paclitaxel-coated balloon angioplasty in femoropopliteal artery disease: Results of the CRESCENT study.","authors":"Naoki Yoshioka, Takahiro Tokuda, Akiko Tanaka, Shunsuke Kojima, Kohei Yamaguchi, Takashi Yanagiuchi, Kenji Ogata, Tatsuro Takei, Yasuhiro Morita, Tatsuya Nakama, Itsuro Morishima","doi":"10.1177/1358863X251322731","DOIUrl":"10.1177/1358863X251322731","url":null,"abstract":"<p><strong>Background: </strong>Paclitaxel-coated balloons (PCBs) are widely used for femoropopliteal artery (FPA) diseases. However, data on recurrence and recurrence patterns after PCB angioplasty are limited. This study investigated the association between recurrence patterns, baseline characteristics, and clinical outcomes in the cases following PCB angioplasty.</p><p><strong>Methods: </strong>This multicenter, retrospective study included 1159 limbs in 1031 patients treated for de novo FPA lesions using PCBs. Patients were classified into three groups (patency, restenosis, and reocclusion) according to patency or recurrence patterns within 2 years after the index PCB angioplasty. The primary outcome was the incidence of target lesion revascularization (TLR), and the secondary outcome was the pattern of re-recurrence within 2 years following TLR using PCBs.</p><p><strong>Results: </strong>When comparing the three groups, reocclusive cases were characterized by more complex lesions, including chronic total occlusion, at baseline. Following the index PCB angioplasty, approximately 70% of recurrent cases underwent TLR, which was performed more frequently in reocclusive than in restenotic cases (82.1% vs 63.7%). Conversely, a higher percentage of restenotic cases did not require TLR compared to reocclusive cases (10.3% vs 27.8%). In cases where TLR was performed using PCBs, the rate of re-recurrence with occlusive morphology was significantly higher in reocclusive than in restenotic cases (52.3% vs 24.3%).</p><p><strong>Conclusions: </strong>After PCB angioplasty for FPA lesions, symptomatic recurrence and requirement for TLR were more frequent in reocclusive cases. Even after TLR using PCBs, reocclusive cases tend to recur with occlusion.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"439-448"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-04-21DOI: 10.1177/1358863X251326537
Mauricio Gonzalez-Urquijo, Gustavo Salgado-Garza, Ariana Marie Martin, Jos C van den Berg, Jose Francisco Vargas, Leopoldo Marine, Francisco Valdes, Mario Alejandro Fabiani
The present review introduces the term 'infective native visceral artery aneurysm (INVAA)' and provides a systematic review of the literature on this topic. The terms 'mycotic' and 'infected' have been replaced by the term 'infective native' to more accurately describe aneurysms of this type. A systematic search of MEDLINE, Embase, Google Scholar, and Scopus databases was performed to identify articles reporting on INVAAs to April 2024. Inclusion criteria encompassed studies describing 'mycotic' or 'infected' primary visceral aneurysms, excluding patients with concurrent aneurysms in the aorta. The search yielded 356 articles, with 161 meeting the inclusion criteria, covering 175 patients. The median age was 48 years (IQR: 33-60 years), predominantly men (n = 127, 72.6%). INVAA was most frequently reported in the superior mesenteric artery (37.5%, n = 65), followed by the hepatic (22.9%, n = 40) and splenic arteries (14.3%, n = 25). Endocarditis was the predominant etiology in 67.4% (n = 118) of cases. Gram-positive pathogens were identified in 58.8% (n = 103) of cases. Treatment modalities included open surgery (49.7%, n = 87), endovascular interventions (37.7%, n = 66), and medical management (12.0%, n = 21). The overall proportion of patients who died was 13.7% (n = 24). In multivariable modeling, cerebral aneurysms (OR: 4.0, 95% CI 1.17, 12.8; p = 0.02), gastrointestinal bleed (OR: 5.79, 95% CI 1.86, 17.6; p < 0.01), and chronic kidney disease (OR: 16.0, 95% CI 2.3, 136; p < 0.01) were associated with increased odds of death. The optimal treatment for INVAA remains undefined, highlighting the need for standardization of reporting and prospective registries to enhance the understanding and management of this complex disease.
{"title":"Infective native visceral artery aneurysm (INVAA): A systematic review of etiology, treatment, and outcomes.","authors":"Mauricio Gonzalez-Urquijo, Gustavo Salgado-Garza, Ariana Marie Martin, Jos C van den Berg, Jose Francisco Vargas, Leopoldo Marine, Francisco Valdes, Mario Alejandro Fabiani","doi":"10.1177/1358863X251326537","DOIUrl":"10.1177/1358863X251326537","url":null,"abstract":"<p><p>The present review introduces the term 'infective native visceral artery aneurysm (INVAA)' and provides a systematic review of the literature on this topic. The terms 'mycotic' and 'infected' have been replaced by the term 'infective native' to more accurately describe aneurysms of this type. A systematic search of MEDLINE, Embase, Google Scholar, and Scopus databases was performed to identify articles reporting on INVAAs to April 2024. Inclusion criteria encompassed studies describing 'mycotic' or 'infected' primary visceral aneurysms, excluding patients with concurrent aneurysms in the aorta. The search yielded 356 articles, with 161 meeting the inclusion criteria, covering 175 patients. The median age was 48 years (IQR: 33-60 years), predominantly men (n = 127, 72.6%). INVAA was most frequently reported in the superior mesenteric artery (37.5%, <i>n</i> = 65), followed by the hepatic (22.9%, <i>n</i> = 40) and splenic arteries (14.3%, <i>n</i> = 25). Endocarditis was the predominant etiology in 67.4% (n = 118) of cases. Gram-positive pathogens were identified in 58.8% (n = 103) of cases. Treatment modalities included open surgery (49.7%, <i>n</i> = 87), endovascular interventions (37.7%, <i>n</i> = 66), and medical management (12.0%, <i>n</i> = 21). The overall proportion of patients who died was 13.7% (n = 24). In multivariable modeling, cerebral aneurysms (OR: 4.0, 95% CI 1.17, 12.8; <i>p</i> = 0.02), gastrointestinal bleed (OR: 5.79, 95% CI 1.86, 17.6; <i>p</i> < 0.01), and chronic kidney disease (OR: 16.0, 95% CI 2.3, 136; <i>p</i> < 0.01) were associated with increased odds of death. The optimal treatment for INVAA remains undefined, highlighting the need for standardization of reporting and prospective registries to enhance the understanding and management of this complex disease.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"510-521"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-06-04DOI: 10.1177/1358863X251340633
Saate Shakil, Daniel Chen, Daniel Isquith, Jamie Sapp, Isabella Pommier, Baocheng Chu, Yin Guo, Gador Canton, Niranjan Balu, Chun Yuan, Thomas Hatsukami, Charles Maynard, Xue-Qiao Zhao, Francis Kim
Background: Inflammation and immune dysregulation are thought to drive residual cardiovascular disease risk among persons living with human immunodeficiency virus (HIV) (PLWH) despite effective viral suppression with antiretroviral therapy (ART).
Methods: We investigated differences in carotid inflammation and atherosclerosis in a longitudinal cohort of virally suppressed PLWH (N = 50; on stable ART with CD4 > 250 cells/mm3, viral load < 200 copies/mL for > 6 months) and HIV-uninfected controls (N = 51) matched for age, sex, hypertension, diabetes, smoking, hyperlipidemia, and family history of premature coronary artery disease (CAD). Participants were ≥ 40 years old at enrollment. Measures of carotid vascular inflammation (Ktrans), neovascularization (Vp), and wall thickness were assessed at baseline, 1 year, and change over 1 year by dynamic contrast-enhanced magnetic resonance imaging (MRI).
Results: Among 101 participants, 8% were women, 42% had hypertension, 52% had hyperlipidemia, 16% had diabetes, and 48% had a family history of CAD. Both PLWH and control participants demonstrated a reduction in systolic and diastolic blood pressures and total cholesterol over 1 year; however, the difference was not significant by HIV status. PLWH had a significant reduction in triglycerides compared with controls (-48.8 vs 12.8 mg/dL, p = 0.026). HIV was not associated with baseline, follow up, or change in markers of systemic inflammation assessed by plasma cytokines, nor vascular inflammation as assessed by Ktrans, Vp, carotid wall thickness, or percent wall volume (a measure of plaque burden).
Conclusion: In contrast to other studies of treated and virally suppressed PLWH, HIV infection was not associated with carotid inflammation or plaque in our hypothesis-generating study.
背景:炎症和免疫失调被认为是人类免疫缺陷病毒(HIV) (PLWH)感染者中残留心血管疾病风险的驱动因素,尽管抗逆转录病毒治疗(ART)能有效抑制病毒。方法:研究病毒抑制PLWH患者颈动脉炎症和动脉粥样硬化的纵向队列(N = 50;接受稳定的抗逆转录病毒治疗,CD4细胞/mm3为250,病毒载量< 200拷贝/mL,持续6个月),而未感染hiv的对照组(N = 51)的年龄、性别、高血压、糖尿病、吸烟、高脂血症和早发性冠状动脉疾病(CAD)家族史相匹配。受试者入组时年龄≥40岁。通过动态对比增强磁共振成像(MRI)评估颈动脉血管炎症(Ktrans)、新生血管(Vp)和壁厚在基线、1年和1年内的变化。结果:在101名参与者中,8%为女性,42%患有高血压,52%患有高脂血症,16%患有糖尿病,48%有冠心病家族史。PLWH和对照组的参与者在1年内均表现出收缩压、舒张压和总胆固醇的降低;然而,艾滋病毒感染状况的差异并不显著。与对照组相比,PLWH组甘油三酯显著降低(-48.8 mg/dL vs 12.8 mg/dL, p = 0.026)。HIV与基线、随访或血浆细胞因子评估的全身性炎症标志物的变化无关,也与血管炎症(通过Ktrans、Vp、颈动脉壁厚度或壁体积百分比(衡量斑块负担)评估)无关。结论:与其他治疗和病毒抑制PLWH的研究相反,在我们的假设生成研究中,HIV感染与颈动脉炎症或斑块无关。
{"title":"Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imaging.","authors":"Saate Shakil, Daniel Chen, Daniel Isquith, Jamie Sapp, Isabella Pommier, Baocheng Chu, Yin Guo, Gador Canton, Niranjan Balu, Chun Yuan, Thomas Hatsukami, Charles Maynard, Xue-Qiao Zhao, Francis Kim","doi":"10.1177/1358863X251340633","DOIUrl":"10.1177/1358863X251340633","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and immune dysregulation are thought to drive residual cardiovascular disease risk among persons living with human immunodeficiency virus (HIV) (PLWH) despite effective viral suppression with antiretroviral therapy (ART).</p><p><strong>Methods: </strong>We investigated differences in carotid inflammation and atherosclerosis in a longitudinal cohort of virally suppressed PLWH (<i>N</i> = 50; on stable ART with CD4 > 250 cells/mm<sup>3</sup>, viral load < 200 copies/mL for > 6 months) and HIV-uninfected controls (<i>N</i> = 51) matched for age, sex, hypertension, diabetes, smoking, hyperlipidemia, and family history of premature coronary artery disease (CAD). Participants were ≥ 40 years old at enrollment. Measures of carotid vascular inflammation (<i>K<sup>trans</sup></i>), neovascularization (<i>V<sub>p</sub></i>), and wall thickness were assessed at baseline, 1 year, and change over 1 year by dynamic contrast-enhanced magnetic resonance imaging (MRI).</p><p><strong>Results: </strong>Among 101 participants, 8% were women, 42% had hypertension, 52% had hyperlipidemia, 16% had diabetes, and 48% had a family history of CAD. Both PLWH and control participants demonstrated a reduction in systolic and diastolic blood pressures and total cholesterol over 1 year; however, the difference was not significant by HIV status. PLWH had a significant reduction in triglycerides compared with controls (-48.8 vs 12.8 mg/dL, <i>p</i> = 0.026). HIV was not associated with baseline, follow up, or change in markers of systemic inflammation assessed by plasma cytokines, nor vascular inflammation as assessed by <i>K<sup>trans</sup></i>, <i>V<sub>p</sub></i>, carotid wall thickness, or percent wall volume (a measure of plaque burden).</p><p><strong>Conclusion: </strong>In contrast to other studies of treated and virally suppressed PLWH, HIV infection was not associated with carotid inflammation or plaque in our hypothesis-generating study.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"449-459"},"PeriodicalIF":3.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-03-13DOI: 10.1177/1358863X251315071
Smaragda Lampridou, Tania Domun, Javiera Rosenberg, Rachael Lear, Alun Huw Davies, Mary Wells, Gaby Judah
Adherence to guideline-recommended therapies for peripheral artery disease (PAD), including pharmacotherapy (antiplatelet, lipid-lowering, and antihypertensive agents) and lifestyle modifications (smoking cessation, diet, weight management, and physical activity) remains low. Though single-component interventions targeting smoking cessation, exercise, or medication adherence show some efficacy, comprehensive multicomponent interventions are vital for addressing the complexity of PAD management. This review systematically synthesized multicomponent interventions for patients with PAD. A systematic search was conducted in Embase, MEDLINE, Cochrane Library, APA PsycINFO, CINAHL, Web of Science Core Collection, ProQuest, and Google Scholar to identify primary research describing multicomponent interventions supporting PAD treatment adherence, published between 2007 and 2024. A narrative synthesis was reported using the Template for Intervention Description and Replication (TIDieR) checklist and the behavioral change techniques (BCT) taxonomy. Out of 15 studies (2462 patients, 60.4% men) included in this review, only two addressed all guideline-recommended treatment aspects. Key intervention components included structured exercise (12/15) and education programs (10/15). Most interventions were delivered by multidisciplinary teams in hospital settings over 3 months. Only one study employed behavioral theory in its development, and most interventions (13/15) focused on the BCT 'instructions on how to perform a behavior' rather than diverse BCTs. No interventions significantly increased adherence to all PAD therapies. Few studies measured the intervention's impact on adherence, making it difficult to determine effective intervention characteristics. Most interventions lacked behavioral science approaches and were not designed to address specific adherence determinants. Future interventions should incorporate these elements to effectively address patients' needs. Open Science Framework Registry ID: osf.io/7xqzj.
外周动脉疾病(PAD)的指南推荐疗法,包括药物治疗(抗血小板、降脂和降压药)和生活方式改变(戒烟、饮食、体重管理和体育活动)的依从性仍然很低。虽然针对戒烟、运动或药物依从性的单组分干预显示出一些效果,但综合多组分干预对于解决PAD管理的复杂性至关重要。本综述系统地综合了PAD患者的多组分干预措施。在Embase、MEDLINE、Cochrane Library、APA PsycINFO、CINAHL、Web of Science Core Collection、ProQuest和谷歌Scholar中进行了系统检索,以确定2007年至2024年间发表的描述支持PAD治疗依从性的多组分干预措施的主要研究。使用干预描述和复制模板(TIDieR)检查表和行为改变技术(BCT)分类法进行叙事综合。在本综述纳入的15项研究(2462例患者,60.4%为男性)中,只有两项研究涉及指南推荐的所有治疗方面。主要干预内容包括结构化锻炼(12/15)和教育项目(10/15)。大多数干预措施由多学科小组在医院环境中提供,时间超过3个月。只有一项研究在其发展过程中采用了行为理论,大多数干预措施(13/15)侧重于BCT“关于如何执行行为的指示”,而不是各种BCT。无干预显著增加了所有PAD治疗的依从性。很少有研究测量干预对依从性的影响,因此很难确定有效的干预特征。大多数干预措施缺乏行为科学方法,并不是为了解决特定的依从性决定因素而设计的。未来的干预措施应纳入这些要素,以有效地满足患者的需求。开放科学框架注册表ID: osf.io/7xqzj。
{"title":"Multicomponent interventions designed to support adherence to guideline-recommended therapy in patients with peripheral artery disease: A scoping review.","authors":"Smaragda Lampridou, Tania Domun, Javiera Rosenberg, Rachael Lear, Alun Huw Davies, Mary Wells, Gaby Judah","doi":"10.1177/1358863X251315071","DOIUrl":"10.1177/1358863X251315071","url":null,"abstract":"<p><p>Adherence to guideline-recommended therapies for peripheral artery disease (PAD), including pharmacotherapy (antiplatelet, lipid-lowering, and antihypertensive agents) and lifestyle modifications (smoking cessation, diet, weight management, and physical activity) remains low. Though single-component interventions targeting smoking cessation, exercise, or medication adherence show some efficacy, comprehensive multicomponent interventions are vital for addressing the complexity of PAD management. This review systematically synthesized multicomponent interventions for patients with PAD. A systematic search was conducted in Embase, MEDLINE, Cochrane Library, APA PsycINFO, CINAHL, Web of Science Core Collection, ProQuest, and Google Scholar to identify primary research describing multicomponent interventions supporting PAD treatment adherence, published between 2007 and 2024. A narrative synthesis was reported using the Template for Intervention Description and Replication (TIDieR) checklist and the behavioral change techniques (BCT) taxonomy. Out of 15 studies (2462 patients, 60.4% men) included in this review, only two addressed all guideline-recommended treatment aspects. Key intervention components included structured exercise (12/15) and education programs (10/15). Most interventions were delivered by multidisciplinary teams in hospital settings over 3 months. Only one study employed behavioral theory in its development, and most interventions (13/15) focused on the BCT 'instructions on how to perform a behavior' rather than diverse BCTs. No interventions significantly increased adherence to all PAD therapies. Few studies measured the intervention's impact on adherence, making it difficult to determine effective intervention characteristics. Most interventions lacked behavioral science approaches and were not designed to address specific adherence determinants. Future interventions should incorporate these elements to effectively address patients' needs. <b>Open Science Framework Registry ID: osf.io/7xqzj</b>.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"343-352"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-14DOI: 10.1177/1358863X251322177
Kasthuri Nair, Brandi M Mize, Mia S White, Tabia Henry Akintobi, Rachel E Patzer, Shipra Arya, Olamide Alabi
{"title":"Reporting of race, ethnicity, and gender in lower-extremity peripheral artery disease randomized controlled trials.","authors":"Kasthuri Nair, Brandi M Mize, Mia S White, Tabia Henry Akintobi, Rachel E Patzer, Shipra Arya, Olamide Alabi","doi":"10.1177/1358863X251322177","DOIUrl":"10.1177/1358863X251322177","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"315-317"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-03-03DOI: 10.1177/1358863X251322182
Georgia R Parsons, Gomathy Parvathinathan, Ali Etemadi, Sai Liu, Elsie Ross, W Schuyler Jones, Margaret R Stedman, Tara I Chang
{"title":"Identifying peripheral artery disease in persons with and without chronic kidney disease from electronic health records.","authors":"Georgia R Parsons, Gomathy Parvathinathan, Ali Etemadi, Sai Liu, Elsie Ross, W Schuyler Jones, Margaret R Stedman, Tara I Chang","doi":"10.1177/1358863X251322182","DOIUrl":"10.1177/1358863X251322182","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"312-314"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-09DOI: 10.1177/1358863X251320917
Natalie S Evans, Alexandra L Solomon, Elizabeth V Ratchford
{"title":"Vascular Disease Patient Information Page: Peripheral artery disease - 2025 update.","authors":"Natalie S Evans, Alexandra L Solomon, Elizabeth V Ratchford","doi":"10.1177/1358863X251320917","DOIUrl":"10.1177/1358863X251320917","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"384-388"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-06-16DOI: 10.1177/1358863X251340018
J Blake Iceton, Stanislav Henkin, Daniella Kadian-Dodov, Danielle Vlazny
{"title":"A day in the life of a vascular medicine specialist and highlights from the 2025 SVM Fellows and APP course.","authors":"J Blake Iceton, Stanislav Henkin, Daniella Kadian-Dodov, Danielle Vlazny","doi":"10.1177/1358863X251340018","DOIUrl":"https://doi.org/10.1177/1358863X251340018","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":"30 3","pages":"395-399"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-06-16DOI: 10.1177/1358863X251332960
Geoffrey D Barnes
{"title":"Implementation science in vascular medicine: Translating research findings into everyday practice.","authors":"Geoffrey D Barnes","doi":"10.1177/1358863X251332960","DOIUrl":"https://doi.org/10.1177/1358863X251332960","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":"30 3","pages":"278-280"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}